Key Takeaways
- • mbiomics completed its €30 million Series A funding round in three tranches, with the final €12 million closing providing capital to build proprietary manufacturing facilities for complex microbial products.
- • MIG Fonds and Bayern Kapital, existing investors, continued backing the Munich-based biotech company founded in 2020 by Dr. Laura Figulla, Dr. Markus Rinecker, and Dr. Johannes B. Woehrstein.
- • The company's lead candidate, MBX-116, targets second-line melanoma patients receiving immune checkpoint inhibitors, addressing a population with historically low response rates where microbiome intervention has demonstrated clinical potential.
- • mbiomics employs AI, machine learning, advanced analytics, and high-throughput screening to design complex microbial consortia, addressing scalability and regulatory inconsistencies plaguing traditional fecal microbiota transplants (FMT).
- • Beyond oncology, the company is developing treatments for autoimmune and neurodegenerative diseases, positioning itself in the growing live biotherapeutics market alongside competitors including Vedanta Biosciences, Enterome, and 4D Molecular Therapeutics.
Summary
mbiomics, a Munich-based live biotherapeutics company, has closed a €30 million Series A funding round following completion of its third and final tranche, which raised €12 million. The structured three-part funding approach was designed to support the company's infrastructure buildout, specifically the construction of proprietary manufacturing facilities for complex microbial products. Existing investors MIG Fonds and Bayern Kapital participated in the closing, demonstrating sustained confidence in the company's platform and clinical trajectory.
Founded in 2020 by Dr. Laura Figulla, Dr. Markus Rinecker, and Dr. Johannes B. Woehrstein, mbiomics addresses a significant market gap between early-stage microbiome research and commercial-scale pharmaceutical manufacturing. The company's core technology platform leverages artificial intelligence, machine learning, advanced analytics, large-scale co-cultivation techniques, and high-throughput screening to design rationally engineered microbial consortia—a substantial departure from conventional fecal microbiota transplant (FMT) approaches, which suffer from inconsistency, limited scalability, and mounting regulatory complexity.
The company's lead clinical asset, MBX-116, represents a co-therapeutic approach for second-line melanoma patients receiving immune checkpoint inhibitors—a population characterized by suboptimal response rates where microbiome-immune system interactions have established mechanistic relevance. This indication reflects growing clinical evidence linking gut microbiota composition to immunotherapy efficacy. Beyond oncology, mbiomics is advancing programs in autoimmune and neurodegenerative diseases, capitalizing on expanding research into gut-brain and gut-immune axis pathways.
The €30 million raise positions mbiomics within a competitive live biotherapeutics landscape that includes established players such as Vedanta Biosciences, Enterome, and 4D Molecular Therapeutics. With manufacturing infrastructure now in place following the Series A close, the company is positioned to transition from platform validation toward clinical advancement and potential regulatory submissions in the coming years.
Founded in 2020 by Dr. Laura Figulla, Dr. Markus Rinecker, and Dr. Johannes B. Woehrstein, mbiomics addresses a significant market gap between early-stage microbiome research and commercial-scale pharmaceutical manufacturing. The company's core technology platform leverages artificial intelligence, machine learning, advanced analytics, large-scale co-cultivation techniques, and high-throughput screening to design rationally engineered microbial consortia—a substantial departure from conventional fecal microbiota transplant (FMT) approaches, which suffer from inconsistency, limited scalability, and mounting regulatory complexity.
The company's lead clinical asset, MBX-116, represents a co-therapeutic approach for second-line melanoma patients receiving immune checkpoint inhibitors—a population characterized by suboptimal response rates where microbiome-immune system interactions have established mechanistic relevance. This indication reflects growing clinical evidence linking gut microbiota composition to immunotherapy efficacy. Beyond oncology, mbiomics is advancing programs in autoimmune and neurodegenerative diseases, capitalizing on expanding research into gut-brain and gut-immune axis pathways.
The €30 million raise positions mbiomics within a competitive live biotherapeutics landscape that includes established players such as Vedanta Biosciences, Enterome, and 4D Molecular Therapeutics. With manufacturing infrastructure now in place following the Series A close, the company is positioned to transition from platform validation toward clinical advancement and potential regulatory submissions in the coming years.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.